Preemptive Strike With Bortezomib in Multiple Myeloma Patients

Inclusion Criteria: * Diagnosed with multiple myeloma currently or previously enrolled on UARK 98-026 and currently event-free at the time of the evaluation. * Performance status of 0-2 based of Southwest Oncology Group (SWOG) criteria * Previously documented platelet count \> 75,000/ul within a 35 days prior to enrollment * Previously documented peripheral absolute neutrophil count \>1,000/ul within 35 days prior to enrollment. * Adequate renal function * Signed informed consent * Female subject is post-menopausal or willing to use acceptable birth control * Male subjects agree to use acceptable method of contraceptive Exclusion Criteria: * Hypersensitivity to Bortezomib, boron, or mannitol * Female subject is pregnant or breastfeeding * Experienced myocardial infraction within 6 months prior to enrollment * Received other investigational new drugs within 14 days before enrollment * Received any anti-myeloma therapy within 14 days * Serious medical or psychiatric illness likely to interfere with participation in this clinical study * Diagnosed or treated for another malignancy within 3 years of enrollment